| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
TransCode Therapeutics, Inc.$8.83
-0.77 (-7.97%)
C 47Pipeline Score Undervalued Biotech · Clinical
Market Cap
5.93 M
EPS
-48.65
P/E Ratio
-
Value Trade
12.50 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
5.11 M
Operating CF
-4.98 M
Total Assets
157.16 M
Total Liabilities
12.64 M
Equity
1.25 M
D/E Ratio
12,345
-10.73 %
Week
-27.36 %
1 Month
-38.82 %
3 Month
-26.42 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
12.84 M
Monthly Burn
1.66 M
Runway
6.1 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
59.60 K
52 Week Range
5.56 - 20.99
% held by Insiders
8.76 %
% held by Institutions
3.25 %
Enterprise Value
136.36 M
Total Shares
916.97 K
Short %
6.5 %
Float Shares
832.61 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for TransCode Therapeutics, Inc.
265Total events
5Upcoming
29Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 5
Event history 260
Jun 18, 2026
◆R&D DayPresentation
R&D Webcast to provide strategic, scientific, and clinical program updates
Jun 11, 2026
▲Partnership / LicenseCorporate
Licensing of immuno-oncolytic portfolio from Unleash Immuno Oncolytics
Jun 11, 2026
▼Equity OfferingCorporate
Series C Preferred $20 million SEPA transaction with Yorkville Advisors
Jun 8, 2026
▲Trial InitiationTTX-MC138Trial
Phase 2a clinical trial of TTX-MC138 initiated
ctDNA-positive colorectal cancersource ↗
Jun 8, 2026
◆Enrollment UpdateTTX-MC138Trial
Phase 2a trial beginning enrollment
ctDNA-positive colorectal cancersource ↗
Jun 3, 2026
Jun 3, 2026
May 27, 2026
▲Trial InitiationTTX-MC138Trial
Initiation of Phase 2a clinical trial of TTX-MC138 in patients with ctDNA positive colorectal cancer
ctDNA positive colorectal cancersource ↗
Apr 27, 2026
▲Management ChangeCorporate
Appointment of Dr. Anna Moore as Chair of Scientific Advisory Board
Apr 27, 2026
Apr 7, 2026
Drug Pipeline Intelligence
C47
Pipeline Score $63M
Pipeline ValueUndervalued
Valuation Signal2
Drugs Scored10.8x
rNPV / MCap Top 69%
Micro Cap (rank 283 of 911)
Percentile RankTransCode Therapeutics, Inc. carries a moderate pipeline score (47/100), with $6.8B risk-adjusted pipeline value, led by TTX-MC138 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TTX-MC138-NODAGA-Cu64 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05908773 | 10% | $3.4B | COMPLETED | 1 | - | - | Sep 18, 2023 | - | Jan 28, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TTX-MC138 Orphan | metastatic cancer | Phase 1a | 2026-06-03 | no dose-limiting toxicities, durable disease stabilization in metastatic patients Read More | TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer Read More | |
TTX-MC138 Orphan | metastatic cancer | Phase 1a | 2026-06-03 | no dose-limiting toxicities, durable disease stabilization in metastatic patients Read More | TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer Read More | |
TTX-MC138 Orphan | metastatic cancer | Phase 1a | 2026-06-03 | no dose-limiting toxicities, durable disease stabilization in metastatic patients Read More | TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RNAZ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RNAZ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RNAZThree Platforms, One Mission: Transforming Advanced Cancer Care NASDAQ: RNAZ Company Forward Looking Statement 2 Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the  
TransCode Therapeutics (RNAZ) is focused on advancing cancer care through its innovative three-platform approach aimed at enhancing treatment for metastatic cancer. The company is prioritizing the clinical development of TTX-MC138, with several key catalysts anticipated in the upcoming 18 months, including trial enrollment milestones and data readouts. TransCode aims to leverage a balanced portfolio to drive innovation and potentially secure significant clinical advancements in the oncology sector.
Read more →RNAZ▼ -9.1%on this newsshared move
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
TransCode Therapeutics will host a live R&D webcast on June 18, 2026, to discuss updates on its Phase 2a trial of TTX-MC138 for colorectal cancer. The event will cover the company's three-platform pipeline and investment strategies. Key speakers include prominent figures from the medical and scientific community.
Read more →RNAZTransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
TransCode Therapeutics has successfully completed its Phase 1a clinical trial for TTX-MC138, demonstrating safety and durable disease stabilization in metastatic cancer patients. The trial met its primary endpoint with no dose-limiting toxicities. Following these promising results, the company plans to advance TTX-MC138 into Phase 2a development, focusing on ctDNA-positive colorectal cancer.
Read more →RNAZ▼ -5.6%on this news
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
TransCode Therapeutics has initiated a Phase 2a clinical trial for TTX-MC138, targeting patients with ctDNA positive colorectal cancer post-curative therapy. The trial aims to evaluate the drug's effectiveness in reducing cancer recurrence risk. Conducted in collaboration with Quantum Leap Healthcare, it will enroll up to 45 patients and is expected to provide valuable data on ctDNA testing.
Read more →RNAZTransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board and signed a sponsored research agreement with Michigan State University. Dr. Moore, a co-founder of TransCode, will guide the company's research on RNA-based cancer therapies. The agreement aims to accelerate the development of TransCode's pipeline candidates, including TTX-MC138, in combination with other therapies.
Read more →RNAZTransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
TransCode Therapeutics has entered into a financing agreement with an institutional investor for up to $20 million, which includes a pre-paid advance and a Standby Equity Purchase Agreement. This funding aims to support the ongoing Phase 2a trial of TTX-MC138, a candidate targeting metastatic cancers. The financing enhances the company's operational runway into late 2027 or early 2028.
Read more →RNAZTransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode Therapeutics has entered into a royalty-free license agreement with Unleash Immuno Oncolytics to develop three drug candidates, including UIO-524, aimed at treating muscle-invasive bladder cancer. This acquisition enhances TransCode's oncology pipeline and addresses significant unmet medical needs. The agreement involves a one-time payment in the form of preferred stock, representing a notable expansion for the company.
Read more →RNAZTransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
TransCode Therapeutics announced the publication of a study on its RIG-I immunotherapeutic candidate, highlighting a novel approach that activates immune signaling in cancer cells while allowing for non-invasive imaging. The research, conducted in collaboration with Michigan State University, addresses challenges of off-target activation and delivery inefficiencies. The findings support further development of TransCode's TTX nanoparticle delivery platform in clinical settings.
Read more →RNAZ▲ +16.2%on this news
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
TransCode Therapeutics has submitted an IND amendment for a Phase 2a trial of TTX-MC138, aimed at colorectal cancer patients. This trial, part of the PRE-I-SPY program, will enroll up to 45 patients with positive ctDNA markers. The study seeks to assess the drug's effectiveness in improving long-term cancer outcomes and is set to begin in the first half of 2026.
Read more →RNAZTransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics announced the publication of preclinical research validating the therapeutic potential of TTX-MC138 for glioblastoma multiforme (GBM). The study, published in the Journal of Functional Biomaterials, shows that TTX-MC138 can deliver antisense oligonucleotides effectively to tumors in murine models, leading to extended survival rates. These findings support the drug's advancement into further clinical trials aimed at treating aggressive GBM.
Read more →RNAZABCJ, LLC Reports and Financial Statements For the years ended
ABCJ, LLC has released its consolidated financial statements for the years ending December 31, 2024 and 2023, showcasing a decline in financial performance. The company reported a net loss of $16,351 for the year 2024, an increase from $11,515 in 2023. Additionally, the accumulated deficit grew to $193,090, further emphasizing the company's ongoing financial struggles. Despite these challenges, the members' equity saw a slight increase from $17,633 in 2023 to $17,782 in 2024.
Read more →RNAZTransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics has appointed Jack E. Stover to its Board of Directors, enhancing its leadership team. Stover, with over 30 years of experience in life sciences, will contribute to the Audit and Nominating Committees. His background in drug development and strategic growth is seen as a valuable asset as the company progresses in its RNA and immuno-oncology pipeline.
Read more →RNAZTransCode Expands Leadership with Appointment of Jack E. Stover to Board of Directors BOSTON
TransCode Therapeutics has announced the appointment of Jack E. Stover to its Board of Directors, bringing over 30 years of leadership experience in life sciences. Stover will serve on the Audit and Nominating Committees, filling the position left by Dr. Magda Marquet. His expertise is expected to boost TransCode's pipeline in RNA and immuno-oncology as the company progresses its clinical initiatives.
Read more →RNAZ▲ +20.7%on this news
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode
TransCode Therapeutics and Quantum Leap Healthcare Collaborative have initiated a Phase 2a dose-expansion trial for TTX-MC138, targeting colorectal cancer patients at risk of recurrence. The trial will evaluate the drug's efficacy in patients who have shown a positive response to standard curative therapies but still show evidence of circulating tumor DNA. This initiative follows positive results from a Phase 1a trial, which established TTX-MC138's safety and potential clinical benefits. The trial aims to fill an unmet need in cancer treatment by addressing Minimal Residual Disease and aims to begin enrollment in the first half of 2026.
Read more →RNAZTransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics has appointed Dr. Michel Janicot as Senior Development Officer to enhance its oncology pipeline. Dr. Janicot, with over 35 years of experience, will initially work part-time and focus on advancing the company's lead programs. His expertise in RNA biology and oncology strategy is expected to be crucial for the company's growth.
Read more →RNAZ▲ +5.6%on this news
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
TransCode Therapeutics has completed its Phase 1a trial for TTX-MC138, an inhibitor of microRNA-10b, successfully meeting safety endpoints and establishing a recommended Phase 2 dose. The trial involved 16 patients, with no significant safety events reported. Positive pharmacodynamic effects were observed, leading to plans for a Phase 2a trial to further evaluate efficacy in metastatic diseases.
Read more →RNAZ▲ +21.1%on this news
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
TransCode Therapeutics has announced the acquisition of Polynoma LLC, a biotechnology company specializing in immuno-oncology. This acquisition, along with a $25 million investment from CK Life Sciences, aims to advance TransCode's lead microRNA asset, TTX-MC138, into Phase 2 clinical trials. The strategic move is expected to enhance TransCode's pipeline and address metastatic melanoma treatment.
Read more →RNAZTransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
TransCode Therapeutics has appointed Dr. Phillip D. Zamore to its Scientific Advisory Board. Dr. Zamore is known for his pioneering work in RNA interference and has co-founded Alnylam Pharmaceuticals. His expertise is expected to significantly contribute to TransCode's development of RNA-targeted cancer therapies, particularly in treating metastatic disease.
Read more →RNAZTransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
TransCode Therapeutics has successfully completed the initial dosing of patients in Cohort 4 of its Phase 1a clinical trial for TTX-MC138, with no dose limiting toxicities reported. The trial has enrolled 15 patients across various dose levels, and ongoing analysis shows promising pharmacokinetic and pharmacodynamic results. The trial aims to further evaluate the safety and potential anti-tumor activity of TTX-MC138.
Read more →RNAZ▼ -14.3%on this newsshared move
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
TransCode Therapeutics has announced a 1-for-28 reverse stock split effective May 15, 2025. This move aims to increase the trading price of its common stock to comply with Nasdaq listing requirements. The split will reduce the number of outstanding shares significantly and will be automatically adjusted for stockholders. However, there are no guarantees that the company will meet all Nasdaq requirements post-split.
Read more →RNAZ▼ -9.2%on this news· ran to -37% by day 3shared move
: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
TransCode Therapeutics has announced a 1-for-28 reverse stock split approved by its Board of Directors to comply with Nasdaq's minimum bid price requirement. This move is expected to reduce the number of shares outstanding from approximately 23 million to about 833,620 shares. The company aims to enhance its stock price in a bid to maintain its listing on the Nasdaq Capital Market. The reverse stock split's effective date will be announced in the future, along with adjustments to outstanding stock options and warrants.
Read more →RNAZ▼ -9.2%on this news· ran to -37% by day 3shared move
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
TransCode Therapeutics has announced a 1-for-28 reverse stock split approved by its Board of Directors and stockholders. The purpose of this split is to increase the trading price of the company's common stock to meet the minimum bid price requirement for Nasdaq listing. The split will reduce the number of shares outstanding significantly and aims to facilitate compliance with market regulations. The effective date of the split will be announced two business days prior to its implementation.
Read more →RNAZTransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
TransCode Therapeutics has reported progress in its Phase 1a clinical trial of TTX-MC138 for metastatic cancer, with 13 patients treated so far. The trial has shown no dose limiting toxicities, and preliminary data indicates a favorable pharmacokinetic and pharmacodynamic profile. The company plans to advance to the Phase 1b portion to further evaluate the safety and anti-tumor activity of TTX-MC138.
Read more →RNAZTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics, Inc. has announced the adjournment of its Special Meeting initially scheduled for April 21, 2025, due to insufficient quorum. The meeting will now reconvene on May 2, 2025, to solicit additional votes on key proposals. Stockholders are encouraged to vote before the new deadline to ensure their participation.
Read more →RNAZ▼ -10.4%on this news· ran to -32% by day 1shared move
An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split if Necessary
TransCode Therapeutics, Inc. has issued an open letter to its shareholders requesting approval for a reverse stock split in order to maintain its NASDAQ listing as the share price trades below $1.00. Although the company has raised $18M in recent financings and is progressing with its clinical trial, it acknowledges the need for additional capital in a challenging market. The deadline for voting on this proposal is set for April 20, 2025, and the management believes the split is critical for future funding opportunities.
Read more →RNAZ▼ -11.9%on this news
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
TransCode Therapeutics, Inc. announced the initial dosing of the first patient in Cohort 4 of its Phase 1 clinical trial using TTX-MC138, aimed at inhibiting microRNA-10b linked to metastatic cancer. Ten patients have been treated across all cohorts without significant safety issues. Further evaluations are underway to expand the patient enrollment in Cohort 3, while ongoing data analysis supports the safety and dosage strategies of the drug. TTX-MC138 is designed to address challenges in treating metastatic tumors.
Read more →RNAZTransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
TransCode Therapeutics, Inc. has announced the successful closing of a registered direct offering of 10,250,000 shares, raising about $10 million. The funds will be used primarily for product development, including clinical trials for its lead candidate, TTX-MC138. Additionally, TransCode's offering was conducted under an effective shelf registration statement with the SEC. Despite the positive fundraising outcomes, the company is exposed to various risks associated with drug development and financial stability.
Read more →RNAZ▼ -38.2%on this news· ran to -54% by day 3shared move
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
TransCode Therapeutics, Inc. has announced a registered direct offering of 10,250,000 shares and warrants priced at-the-market under Nasdaq rules, expected to close on March 25, 2025. The company anticipates raising approximately $10 million in gross proceeds to fund product development activities, particularly clinical trials for its lead candidate, TTX-MC138. The offering's completion depends on customary closing conditions and the company has acknowledged various risks associated with drug discovery and competition in the market.
Read more →RNAZ▼ -27.3%on this news
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
TransCode Therapeutics has received approval from its Safety Review Committee to open the fourth cohort of patients in its Phase I/II clinical trial for TTX-MC138, designed to treat metastatic cancers. The decision was based on favorable safety data from prior cohorts, with no significant dose-limiting toxicities reported. Six out of nine patients from the first three cohorts continue to receive treatment, indicating the tolerability of the candidate. The approval allows for additional patient enrollment in the trial as the company continues to explore the therapeutic potential of TTX-MC138.
Read more →RNAZ▼ -36.7%on this news· ran to -71% by day 3
TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics, Inc. held its Special Meeting on February 25, 2025, where shareholders voted on two key proposals. The first proposal, aimed at approving the issuance of shares related to the Series C and D Warrants, received majority approval. The second proposal to adjourn the meeting for further solicitation of proxies was also approved by a majority. TransCode aims to enhance cancer treatment through its proprietary RNA therapeutics platform.
Read more →RNAZ▲ +27.2%on this news
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics announced the completion of initial dosing in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, its lead candidate targeting metastatic cancers. The Safety Review Committee approved this phase based on previous cohorts' safety data, reporting no significant adverse effects. Patients from earlier cohorts continue to receive treatment, and preliminary analyses suggest favorable pharmacokinetic properties consistent with earlier studies. This trial aims to evaluate safety, tolerability, and potential clinical activity of TTX-MC138 across different metastatic solid tumors.
Read more →RNAZ▲ +5.7%on this news
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics has successfully dosed the first patient in Cohort 3 of its Phase 1 clinical trial for TTX-MC138. This follows a favorable assessment from the Safety Review Committee based on safety data from the first two cohorts, which reported no significant adverse effects. The trial focuses on evaluating the safety and tolerability of TTX-MC138 in patients with metastatic solid tumors, leveraging positive pharmacokinetic and pharmacodynamic data obtained in earlier phases.
Read more →RNAZNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced it has regained compliance with Nasdaq's listing rules concerning minimum bid price and shareholders' equity. This compliance follows shareholder approval of a July 2024 equity transaction. The company will be monitored for compliance until December 2025. CEO Tom Fitzgerald highlighted the importance of advancing their lead candidate, TTX-MC138, in their clinical program as key to achieving milestones in the coming year.
Read more →RNAZ▼ -37.9%on this news
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics has received approval from its Safety Review Committee to open the third cohort of patients in its Phase 1 clinical trial for TTX-MC138. There were no significant safety issues reported in the second cohort, which allows for treatment with an increased dose in the next patient group. Data from the first cohort corroborate earlier findings, indicating that TTX-MC138 effectively inhibits microRNA-10b, a factor in metastatic cancer progression. Enrollment for new patients in Cohort 3 is now underway.
Read more →RNAZTransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics has announced a 1-for-33 reverse stock split effective December 4, 2024. This move, approved by the Board and stockholders, aims to increase the stock price to comply with Nasdaq's minimum bid requirements. The split will reduce outstanding shares significantly and adjust stock options accordingly. However, there are no assurances that the company will meet all Nasdaq listing criteria.
Read more →RNAZTransCode Therapeutics, Inc. Announces $8 Million Private Placement
TransCode Therapeutics, Inc. has announced an $8 million private placement with institutional investors. The funds will be used for corporate purposes and working capital. The company plans to issue over 21 million shares and warrants, with the closing expected around November 29, 2024. The offering is exempt from registration under the Securities Act.
Read more →RNAZTransCode Therapeutics Announces 1-for-33 Reverse Stock Split
TransCode Therapeutics has announced a 1-for-33 reverse stock split approved by its Board of Directors and stockholders. This move is intended to raise the company's stock price to meet Nasdaq listing requirements. The split will reduce the number of outstanding shares significantly while ensuring stockholders receive whole shares. The effective date for the split is still pending.
Read more →RNAZTransCode Therapeutics Open Letter to Shareholders
TransCode Therapeutics has issued an open letter to shareholders regarding a proposed reverse stock split. This measure is necessary to maintain their Nasdaq listing, contingent on the stock price meeting specific requirements. The management emphasizes the importance of shareholder support to avoid potential delisting and ensure continued operations and funding for clinical trials.
Read more →RNAZTransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has received an extension from Nasdaq to maintain its listing, contingent on meeting specific compliance requirements. As part of this extension, the company received a Public Reprimand Letter following a hearing held on October 1, 2024. TransCode is focused on developing RNA therapeutics for cancer treatment, particularly its lead candidate that targets metastatic tumors. Despite the positive news regarding Nasdaq compliance, the company still faces significant risks related to drug development and financing.
Read more →RNAZTransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
TransCode Therapeutics announced the Safety Review Committee's approval to open the second cohort in its Phase 1 clinical trial for TTX-MC138, following a favorable review of safety data from the first cohort. The trial aims to evaluate the safety and tolerability of TTX-MC138, which targets microRNA-10b associated with metastatic cancer. No significant safety issues were reported in the initial cohort, allowing for dose escalation in the next group of patients.
Read more →RNAZTransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics has successfully completed the initial dosing of the first cohort in its Phase 1a clinical trial for TTX-MC138, a candidate targeting microRNA-10b, which is linked to metastatic cancer. No significant safety concerns have been reported, allowing for continued assessment of the drug's safety and tolerability. The trial aims to evaluate TTX-MC138's effects on various metastatic solid cancers.
Read more →RNAZTransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics has announced the dosing of the first two patients in its Phase 1 clinical trial for TTX-MC138, a first-in-class therapeutic candidate targeting metastatic cancers. The trial aims to evaluate the safety and tolerability of TTX-MC138, with potential implications for treating various cancer types. This milestone is seen as a significant step in the clinical development of the drug.
Read more →RNAZTransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
TransCode Therapeutics, in collaboration with Michigan State University, published a study in Oncotarget detailing the mechanisms behind their lead candidate TTX-MC138's efficacy against metastatic breast cancer. The study reveals that TTX-MC138 reduces stemness in breast cancer cells, which is crucial for metastasis. This research could enhance patient stratification in clinical trials and improve predictions of treatment responses.
Read more →RNAZTransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
TransCode Therapeutics has received a $2 million NIH grant to support the clinical evaluation of its lead candidate, TTX-MC138, in a Phase I/II trial for advanced solid tumors. The trial aims to assess the safety of TTX-MC138, with potential early evidence of clinical activity in metastatic disease. The funding will be distributed over two years.
Read more →RNAZTransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
TransCode Therapeutics has initiated a Phase 1 clinical trial for its lead candidate, TTX-MC138, aimed at evaluating safety and anti-tumor activity. Two clinical trial sites have been activated, with patient enrollment expected to begin this quarter. The trial includes a dose-escalation phase followed by a dose-expansion phase, focusing on metastatic solid cancers. The company showcases strong engagement from leading oncologists, reflecting a promising outlook for its RNA therapeutic strategy.
Read more →RNAZTransCode Therapeutics, Inc. Announces Closing of Public Offering
TransCode Therapeutics, Inc. has successfully completed a public offering of 10 million shares at $0.30 per share, raising $3 million in gross proceeds. The company plans to utilize these funds primarily for product development activities, including clinical trials for its lead candidate, TTX-MC138. The offering was made under an effective registration statement filed with the SEC, with ThinkEquity serving as the sole placement agent. This infusion of capital supports the company's commitment to developing advanced RNA therapeutics for cancer treatment.
Read more →RNAZTransCode Therapeutics, Inc. Announces Pricing of Public Offering
TransCode Therapeutics, Inc. has announced the pricing of a public offering of 10 million shares at $0.30 each, anticipating gross proceeds of $3 million. The offering is expected to close on July 24, 2024, and the funds will be directed primarily towards the development of TTX-MC138, the company's leading therapeutic candidate, as well as for general corporate purposes. The offering is being facilitated by ThinkEquity and is made pursuant to a previously filed shelf registration statement with the SEC.
Read more →RNAZTransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
TransCode Therapeutics, Inc. announced its intention to offer shares of common stock in a public offering to finance product development. The company aims to use the proceeds, notably for clinical trials involving its lead therapeutic candidate TTX-MC138 and other corporate purposes. ThinkEquity will act as the placement agent for the offering, which remains contingent on market conditions. The company emphasizes that this announcement does not constitute a solicitation or offer to buy its securities.
Read more →RNAZTransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics reported promising preliminary data from its Phase 0 clinical trial for TTX-MC138, which indicated significant anti-tumor activity by inhibiting miRNA-10b. The results revealed a 66% reduction in miR-10b levels in a patient’s blood after microdosing. Furthermore, the therapy showed good tolerability with no adverse events. The accumulation of TTX-MC138 in metastatic tumors suggests potential for treating multiple metastatic cancers, supporting its continued clinical development.
Read more →RNAZTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics has received FDA clearance to commence a Phase 1/2 clinical trial for TTX-MC138, targeting advanced solid tumors. The trial aims to evaluate safety and clinical activity, building on promising results from animal studies. This development is seen as a significant milestone for TransCode, as it progresses towards potential novel cancer treatments. The study will begin with a dose-escalation phase before expanding based on initial results.
Read more →RNAZTransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics, Inc. reported its financial results for 2023, highlighting significant advancements in its RNA oncology portfolio. The company advanced its lead candidate, TTX-MC138, into clinical trials and raised over $25 million in equity financing. Despite operating losses and a decrease in cash reserves, TransCode achieved strategic collaborations and positive preliminary results in ongoing trials. Looking ahead, the company aims to initiate a Phase 1 trial of TTX-MC138 and continue developing its therapeutics pipeline throughout 2024.
Read more →RNAZTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics, Inc. has appointed Dr. Daniel Vlock as Chief Medical Officer, bringing over 25 years of experience in oncology and drug development. Dr. Vlock's expertise will contribute to the company's clinical development programs, including the lead candidate, TTX-MC138. His previous roles in managing clinical trials position him well to guide TransCode's efforts in RNA therapeutics for cancer treatment. The appointment is expected to enhance the company's strategic direction and regulatory compliance in upcoming clinical trials.
Read more →RNAZTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
TransCode Therapeutics has announced positive proof-of-concept laboratory studies in collaboration with Akribion Genomics to develop CRISPR-derived technology for cancer treatment. The companies are focusing on combining Akribion's cell-killing G-dase E with TransCode's TTX delivery platform. Initial studies suggest that the resulting ribonucleoprotein complexes could effectively target and induce cancer cell death. While the collaboration shows promise, TransCode emphasizes that there are risks involved in drug discovery and the need for ongoing funding for their initiatives.
Read more →RNAZTransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
TransCode Therapeutics, Inc. announced that its Chief Scientific Officer will present work on TTX-MC138 at the RNA Leaders Europe Congress from March 12-14 in Basel, Switzerland. The presentation will cover the ongoing Phase 0 microdose clinical study for TTX-MC138, which aims to treat metastatic cancer by inhibiting the miR-10b biomarker. Preliminary clinical results and nonclinical studies regarding dosimetry and pharmacokinetics will also be discussed. The company plans to file an IND for a Phase 1/2 trial in March 2024.
Read more →RNAZTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
TransCode Therapeutics has announced the publication of a patent application for a RIG-I agonist immunotherapeutic aimed at treating cancer. This approach utilizes synthetic RNAs to activate immune responses specifically against tumors while minimizing effects on healthy tissues. The company is conducting clinical trials, including a study of its lead candidate, TTX-MC138, which has shown preliminary success in targeting metastatic lesions. Despite the positive advancements, there are uncertainties regarding patent issuance and clinical trial outcomes.
Read more →RNAZNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market BOSTON
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has successfully regained compliance with the minimum stockholders' equity requirement from Nasdaq, allowing it to remain listed on the Nasdaq Capital Market. The company will undergo mandatory monitoring until January 2025. However, if TransCode fails to maintain compliance during this period, it will not be allowed to present a plan for compliance and could face delisting. TransCode is focused on RNA-based treatments for cancer, particularly its lead candidate for metastatic tumors.
Read more →RNAZTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics has entered a co-research agreement with Debiopharm to develop targeted nucleic acid therapeutics for cancer. This collaboration aims to leverage TransCode's TTX delivery platform alongside Debiopharm's expertise to create innovative cancer treatment options. The partnership will focus on developing targeted mRNA delivery systems that could potentially revolutionize cancer therapy outcomes. Financial terms of the agreement were not disclosed.
Read more →RNAZTransCode Therapeutics Announces Closing of $7.25 Million Public Offering
TransCode Therapeutics has announced the successful closing of its public offering, raising $7.25 million through the sale of nearly 6 million shares along with associated warrants. The proceeds will primarily be directed towards advancing the company's lead therapeutic candidate, TTX-MC138, in clinical trials. The offering was facilitated by H.C. Wainwright & Co. and follows a registration statement approval from the SEC. There are inherent risks associated with forward-looking statements regarding the future use of funds and potential compliance issues with Nasdaq regulations.
Read more →RNAZTransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
TransCode Therapeutics, Inc. has announced the pricing of a public offering of approximately 5.94 million shares at $1.22 each, raising gross proceeds of $7.25 million. The funds will be allocated for product development, including clinical trials for their lead candidate, TTX-MC138. The offering is expected to close around January 22, 2024, pending customary closing conditions. H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction.
Read more →RNAZTransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
TransCode Therapeutics is undergoing further restructuring to reduce expenses and focus on its planned Phase 1 clinical trial of TTX-MC138. The CEO, Michael Dudley, is retiring, and Tom Fitzgerald will take over as interim CEO. Enhanced leadership roles have been given to Dr. Zdravka Medarova, now Chief Scientific Officer, and Dr. Philippe Calais, who will serve as Executive Chairman. The company aims to streamline operations and improve its focus on oncology therapeutics based on RNA technology.
Read more →RNAZTransCode Therapeutics Announces 1-for-40 Reverse Stock Split
TransCode Therapeutics, a company focusing on RNA oncology, has announced a 1-for-40 reverse stock split effective January 16, 2024. This measure aims to increase the trading price of its common stock to comply with Nasdaq's minimum bid price requirements. As a result, the number of outstanding shares will be reduced significantly, from about 25 million to approximately 627,448 shares. The reverse split will impact stock options, warrants, and incentive plans proportionally. Forward-looking statements in the announcement highlight risks and uncertainties about the company's future performance post-split.
Read more →RNAZTransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
TransCode Therapeutics has published an open letter to shareholders detailing its progress in 2023 and outlining objectives for 2024. Key highlights include the initiation of a first human clinical trial for its lead candidate, TTX-MC138, and securing $18.5 million in funding during a challenging financial landscape. However, the company has also outlined significant operational streamlining, including workforce reductions and a proposal for a reverse stock split to improve capital-raising potential. Ongoing discussions with industry partners aim to expedite further development of their therapies.
Read more →RNAZTransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
TransCode Therapeutics reported promising preclinical results for its lead candidate, TTX-MC138, in treating metastatic pancreatic cancer. The study demonstrated that TTX-MC138 significantly reduced metastatic burden in animal models compared to untreated and standard chemotherapy controls. This finding highlights its potential to address the substantial unmet clinical need for patients with stage IV pancreatic cancer. The company plans to advance TTX-MC138 into Phase I clinical trials in 2024, further signaling its commitment to innovating cancer treatments.
Read more →RNAZTransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
TransCode Therapeutics, Inc. plans to present Phase 0 clinical trial data for its lead candidate, TTX-MC138, at the San Antonio Breast Cancer Symposium. The study focuses on a miRNA-10b inhibitor that has shown promise in preclinical models. Insights from the trial aim to reveal pharmacokinetics and effectiveness in targeting metastatic cancer. The potential for TTX-MC138 to facilitate future patient selection in clinical trials is also highlighted, emphasizing its significance in cancer treatment innovation.
Read more →RNAZTransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
TransCode Therapeutics, Inc. has announced the closing of a $1.2 million registered direct offering of common stock, with each share priced at $0.242. The funds will primarily be allocated towards clinical trials for its lead candidate, TTX-MC138, aimed at treating metastatic cancer. This offering was facilitated by H.C. Wainwright & Co. under Nasdaq rules, with the company's move reflecting confidence in advancing its oncology pipeline. The announcement highlights TransCode's commitment to developing RNA-based therapeutics targeting various tumor types.
Read more →RNAZTransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
TransCode Therapeutics announced a definitive agreement for a registered direct offering of 5 million shares of common stock at $0.242 per share, expected to close around December 4, 2023. The offering is anticipated to generate approximately $1.2 million in gross proceeds, aimed at funding clinical trials for their lead therapeutic candidate, TTX-MC138. H.C. Wainwright & Co. will serve as the exclusive placement agent for this offering, which is part of a previously filed shelf registration statement. This initiative underscores the company's commitment to advancing its RNA oncology programs.
Read more →RNAZTransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
TransCode Therapeutics, Inc. reported its third quarter 2023 results, detailing financial progress and business updates. The company completed a public offering and commenced its Phase 0 clinical trial for TTX-MC138, dosing its first patient with early indications of successful delivery to metastatic lesions. Promising preclinical data has emerged supporting TTX-MC138's efficacy in glioblastoma and breast cancer models. However, the company reported an increased operating loss and noted that cash on hand may not last beyond early 2024.
Read more →RNAZTransCode Therapeutics Withdraws Public Offering
TransCode Therapeutics, Inc. has withdrawn its underwritten public offering due to current market conditions that are considered unfavorable for the company's interests. This decision highlights the challenges faced by the company in obtaining terms that would benefit stockholders. TransCode is focused on developing RNA therapeutics for cancer treatment, but the withdrawal may raise concerns about investor confidence and market conditions affecting its operational strategies.
Read more →RNAZNasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
TransCode Therapeutics has been granted an extension to maintain its listing on the Nasdaq Stock Market until January 22, 2024, by the Nasdaq Hearings Panel. This extension is contingent upon the company providing updates on its compliance with stockholders' equity requirements by specified deadlines. The panel also reserves the right to reconsider this extension based on any significant developments affecting the company’s compliance. TransCode faces various challenges in drug development and financial stability, which could impact its future listing status.
Read more →RNAZTransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
TransCode Therapeutics announced significant improvements in survival rates for mice with glioblastoma multiforme (GBM) tumors treated with its candidate TTX-MC138, compared to controls. This treatment outperformed the standard chemotherapy temozolomide (TMZ), particularly in cases where resistance to TMZ is common. TransCode is currently enrolling patients in a first-in-human clinical trial to further explore the effects of TTX-MC138 on advanced solid cancers, with the results potentially influencing future clinical dosing strategies. The findings suggest that TTX-MC138 could enhance therapeutic options against one of the most aggressive types of brain cancer.
Read more →RNAZTransCode Therapeutics Announces Public Offering of Common Stock
TransCode Therapeutics has announced an underwritten public offering of its common stock, granting underwriters a 45-day option to purchase additional shares. The offering hinges on market conditions and there are uncertainties regarding its completion and terms. TransCode is focused on advancing RNA therapeutics to treat cancer, with a portfolio of drug candidates aimed at improving patient outcomes.
Read more →RNAZTransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics announced preliminary results from its Phase 0 clinical study involving TTX-MC138 in a patient with metastatic cancer. The results demonstrate the drug's successful delivery to metastatic lesions, with no adverse reactions reported. Preliminary data showed that the drug had pharmacokinetic properties consistent with preclinical studies. While the findings are promising, they are preliminary and should be interpreted with caution as additional data are expected.
Read more →RNAZTransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
TransCode Therapeutics reported positive results from a preclinical study demonstrating that its immunotherapy candidate, TTX-RIGA, effectively treated melanoma tumors by significantly inhibiting their growth. The study revealed that TTX-RIGA not only reduced the primary tumor growth but also produced a notable immune response against recurrent tumors, achieving a 70% inhibition rate. The innovative approach utilizes a targeted activation of innate immunity, prompting optimism for clinical relevance across various solid tumors as the therapeutic candidate moves closer to clinical trials.
Read more →RNAZTransCode Therapeutics Announces Closing of $8.5 Million Public Offering
TransCode Therapeutics, Inc. has closed a public offering that generated $8.5 million in gross proceeds by selling nearly 16.9 million shares of common stock and pre-funded warrants. The proceeds are earmarked for clinical trials involving their lead candidate, TTX-MC138, which aims to treat metastatic cancers, as well as for working capital and general corporate purposes. The offering included the partial exercise of an over-allotment option by underwriters. The registration statement for the offering was declared effective by the SEC on September 25, 2023.
Read more →RNAZTherapeutics Announces Pricing of $8 Million Public Offering
TransCode Therapeutics, Inc. has announced the pricing of an underwritten public offering totaling $8 million, with 15,700,000 shares priced at $0.51 each. The closing of the offering is expected around September 28, 2023, pending customary closing conditions. Proceeds from the offering will support clinical trials for TTX-MC138, the company's lead candidate, which aims to improve the treatment of metastatic cancers. TransCode is focused on innovating RNA therapeutics to enhance cancer treatment outcomes.
Read more →RNAZTransCode Therapeutics Announces Pricing of $8 Million Public Offering
TransCode Therapeutics, Inc. has priced its underwritten public offering at $0.51 per share, aiming to raise approximately $8 million. The proceeds will be allocated towards clinical trials for its lead candidate, TTX-MC138, which targets metastatic cancer. The offering is set to close around September 28, 2023, pending customary conditions. The company has also granted underwriters a 45-day option to purchase additional shares, demonstrating further potential funding opportunities.
Read more →RNAZTransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics announced promising pre-clinical results for its lead therapeutic candidate, TTX-MC138, in treating glioblastoma multiforme (GBM). The study, conducted in murine models, demonstrated effective delivery and engagement of the drug with the tumor, leading to significant inhibition of miRNA-10b, a driver of tumor progression. TransCode is currently enrolling patients in a first-in-human clinical trial to further assess the pharmacokinetics of TTX-MC138.
Read more →RNAZTransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
TransCode Therapeutics has initiated its First-in-Human Phase 0 clinical trial with the successful dosing of the first subject using TTX-MC138, a radiolabeled therapeutic candidate targeting advanced solid tumors. The trial aims to demonstrate the delivery of TTX-MC138 to metastatic lesions and will assess its safety and pharmacokinetics through ongoing monitoring. TTX-MC138 has shown promising preclinical efficacy in various cancers, including triple-negative breast cancer and pancreatic adenocarcinoma. The outcome of this exploratory study could inform future clinical trials and therapeutic strategies against cancer.
Read more →RNAZTransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
TransCode Therapeutics reported its second quarter 2023 financial results and provided a business update, highlighting the advancement of its RNA-targeted therapy, TTX-MC138. The company announced the initiation of patient enrollment for a Phase 0 clinical trial aimed at treating metastatic cancer, along with a funding round that secured $7 million. Despite these advancements, TransCode is facing financial pressures, with cash reserves sufficient only until September 2023, and an increase in operating losses compared to the previous year. The company aims to achieve several important milestones in the coming months.
Read more →RNAZTransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics announced positive outcomes from a study of its lead candidate, TTX-MC138, in non-human primates, demonstrating effective engagement with cancer targets. The therapeutic exhibited favorable pharmacokinetics and strong evidence of efficacy in inhibiting the oncogenic miRNA-10b, linked to various cancers. These findings enhance the prospect of TTX-MC138 as a treatment for advanced solid tumors and support the ongoing enrollment of patients in the first-in-human clinical trial. The company remains optimistic about its potential to improve clinical outcomes for patients with metastatic cancer.
Read more →RNAZTransCode Therapeutics CEO Letter to Shareholders
TransCode Therapeutics provides an update on its advancements in treating metastatic cancer through its lead candidate, TTX-MC138. The company has obtained FDA approval for a first-in-human clinical trial and has reported significant tumor regression in preclinical models. Furthermore, TransCode is expanding its pipeline with several innovative therapeutic candidates and partnerships, notably with MD Anderson Cancer Center. While the biotech sector currently faces challenges, TransCode remains committed to advancing its research and providing viable treatment solutions for cancer patients.
Read more →RNAZTransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
TransCode Therapeutics has published new data regarding its lead candidate, TTX-MC138, which inhibits microRNA-10b and shows promise in treating metastatic breast cancer. The findings, presented at the ASCO annual meeting, indicate that TTX-MC138 may impair the ability of cancer stem cells to generate new tumors. The company has received FDA approval for a first-in-human clinical trial aimed at quantifying TTX-MC138 delivery in cancer patients. The trial will examine its pharmacokinetics, providing critical data for future therapeutic approaches.
Read more →RNAZTransCode Therapeutics Announces Closing of $7 Million Public Offering
TransCode Therapeutics, an RNA oncology company, successfully closed a public offering raising $7 million from the sale of 2,000,000 shares of its common stock, accompanied by warrants. The proceeds will be allocated towards product development activities, including clinical trials for TTX-MC138, its leading candidate targeting metastatic cancer, as well as other therapeutic research. The offering was facilitated by H.C. Wainwright & Co. with a registration statement effective as of June 6, 2023.
Read more →RNAZTransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
TransCode Therapeutics has reported positive preclinical findings for its therapeutic candidate, TTX-MC138, in the treatment of glioblastoma. The study indicates that combining TTX-MC138 with the standard chemotherapy, temozolomide (TMZ), may enhance tumor treatment efficacy. Promising results were observed in animal models, where TTX-MC138 significantly inhibited tumor growth. The company has received IRB approval for a first-in-human clinical trial of TTX-MC138, which will analyze its delivery and pharmacokinetics in patients with advanced solid tumors.
Read more →RNAZTransCode Therapeutics Announces Pricing of $7 Million Public Offering
TransCode Therapeutics has announced a public offering priced at $3.50 per share, aiming to raise $7 million. The offering includes shares and warrants, with net proceeds intended for product development activities, primarily focused on advancing its lead therapeutic candidate, TTX-MC138. The expected closing date for the offering is June 9, 2023, pending customary conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering.
Read more →RNAZTransCode Therapeutics Announces 1-for-20 Reverse Stock Split
TransCode Therapeutics has announced a 1-for-20 reverse stock split effective May 22, 2023. This action aims to increase the per share trading price of its common stock to meet Nasdaq's minimum bid price requirements. The reverse split will reduce the outstanding shares significantly from approximately 17 million to about 850,000. Stockholders will automatically receive their new shares in book-entry form, with fractional shares compensated in cash. TransCode is focused on developing RNA-based therapeutics for various cancers.
Read more →RNAZTransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
TransCode Therapeutics has announced that it has received Institutional Review Board (IRB) approval for its First-in-Human (FIH) Phase 0 clinical trial of TTX-MC138, aimed at treating advanced solid tumors. The trial will evaluate the delivery of TTX-MC138 via a microdose to metastatic lesions in up to 12 patients. This candidate targets microRNA-10b, implicated in cancer metastasis, and has exhibited promising preclinical efficacy in various cancer models. However, the exploratory nature of the trial entails risks, as it is not aimed at proving therapeutic effectiveness.
Read more →RNAZTransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
TransCode Therapeutics announced a strategic expansion of its product portfolio, introducing new capabilities for its TTX delivery platform. This expansion includes a provisional patent application aimed at improving the delivery of RNA and other therapeutic agents. CEO Michael Dudley highlighted the advancements in targeted delivery systems and their application in gene editing and cancer vaccines. The company aims to provide individualized therapies to cancer patients by leveraging its expanding technology and pipeline of therapeutic candidates.
Read more →RNAZTransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
TransCode Therapeutics has announced a Common Stock Purchase Agreement with White Lion Capital, allowing the company to sell up to $1.08 million in common stock. This funding aims to advance the development of TTX-MC138, a promising candidate for treating glioblastomas. The offering will be conducted under a previously filed and effective registration statement with the SEC. Proceeds from the investment are intended for general corporate purposes and working capital.
Read more →RNAZTransCode Therapeutics to present at AACR Annual Meeting 2023
TransCode Therapeutics (NASDAQ: RNAZ) announced its participation in the 2023 AACR Annual Meeting from April 14-19, where it will showcase new results and insights from its clinical studies. The company will present findings related to its RNAi-based checkpoint inhibitor TTX-siPDL1 and its lead therapeutic candidate TTX-MC138, focusing on treating metastatic cancer. The studies indicate successful delivery and therapeutic efficacy, highlighting significant progress toward improving cancer treatment outcomes. This comes alongside the recent FDA approval of the company's First-in-Human Study for TTX-MC138.
Read more →RNAZTransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
TransCode Therapeutics has announced the termination of its planned sale of Series A Convertible Preferred Stock, which was valued at $500,000. The termination occurred after the purchaser indicated it was not ready to proceed under the outlined terms. Consequently, no shares will be issued from this transaction. The company has stated it reserves its legal rights regarding this matter.
Read more →RNAZTransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
TransCode Therapeutics, Inc. has been awarded a nearly $871,000 grant from the NIH for the third year to support the clinical evaluation of its lead therapy candidate, TTX-MC138, aimed at treating advanced solid tumors. The grant will help fund the first-in-human study of TTX-MC138 in patients with metastatic disease, which is expected to commence once Institutional Review Board approval is received. The TTX platform is designed to efficiently deliver RNA therapeutics targeting specific oncogenic pathways, with promising preclinical results noted in various cancer types.
Read more →RNAZTransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
TransCode Therapeutics has announced a definitive securities purchase agreement with Triton Funds for the sale of 60 shares of Series A Convertible Preferred Stock, totaling $500,000. Each share can be converted into common stock at a price of $0.60. This funding could enhance the company's initiatives in treating cancer through its RNA-based therapeutic candidates, which aim to improve patient outcomes across various tumor types.
Read more →RNAZTransCode Therapeutics Reports 2022 Results; Provides Business Update
TransCode Therapeutics reported its 2022 financial results and business updates, highlighting FDA approval for its Phase 0 clinical trial of TTX-MC138 in cancer patients. The company made strides in developing its RNA therapeutics, achieving positive preclinical results in pancreatic cancer and establishing a partnership with the University of Texas MD Anderson Cancer Center. However, it faces financial challenges, with a notable decrease in cash reserves and an increase in operating losses over the past year. Looking ahead, TransCode aims to continue advancing its therapeutic candidates and expects significant upcoming milestones.
Read more →RNAZTransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
TransCode Therapeutics announced that its lead candidate, TTX-MC138, has received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer. This designation highlights the drug's potential in addressing an area of high unmet need, as pancreatic cancer has a very low survival rate. Preclinical studies have indicated that TTX-MC138 could improve clinical outcomes, with complete responses observed in a significant portion of treated models. The company aims to advance its clinical trials to further evaluate this candidate's efficacy in patients with advanced solid tumors.
Read more →RNAZTransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment
TransCode Therapeutics has signed a joint research and development agreement with BRAIN Biotech to collaborate on a CRISPR-derived technology platform aimed at enhancing cancer treatments. This partnership will combine TransCode's TTX nucleic acid delivery system with BRAIN Biotech's G-dase E nuclease to target cancer cells based on RNA biomarkers. The collaboration is seen as a significant step toward advancing new classes of cancer therapies, with the potential for impactful therapeutic targets in oncology.
Read more →RNAZTransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
TransCode Therapeutics, Inc. has successfully completed a registered direct offering, raising $1.5 million by selling 2,846,300 shares of common stock priced at $0.527 each. The offering was facilitated by H.C. Wainwright & Co. and was conducted according to Nasdaq regulations. TransCode is focused on developing RNA therapeutics aimed at effectively treating various cancers, with its lead candidate targeting metastatic cancer, which significantly contributes to cancer mortality worldwide.
Read more →RNAZTransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
TransCode Therapeutics has announced a registered direct offering, selling 2,846,300 shares of common stock at a price of $0.527 each, expected to generate gross proceeds of approximately $1.5 million. The offering is set to close around February 17, 2023, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent for this offering, which follows a previously declared effective registration statement with the SEC. TransCode aims to enhance cancer treatment through its RNA-based therapeutics, particularly its lead candidate TTX-MC138 targeting metastatic cancers.
Read more →RNAZTransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
TransCode Therapeutics reported positive preclinical results for its immunotherapy candidate, TTX-RIGA, targeting melanoma. The candidate aims to activate innate immunity in a tumor-selective manner, leveraging a proprietary nanoparticle delivery system. This approach could enhance the efficacy of cancer treatments while minimizing damage to healthy tissues. TransCode is preparing for animal studies to further evaluate TTX-RIGA's potential in clinical applications.
Read more →RNAZTransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
BOSTON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written authorization from the U.S. Food and Drug Administra
Read more →RNAZTransCode Therapeutics Announces Withdrawal of Registration Statement
BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it withdrew the Registration Statement on Form S-1 it filed w
Read more →RNAZTransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it has submitted an exploratory Investigational New Drug (eIND) application t
Read more →RNAZTransCode Therapeutics Announces eIND Submission
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors BOSTON - November 30, 2022 - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating
Read more →RNAZTransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent busine
Read more →RNAZTransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1, in pancre
Read more →RNAZTransCode Therapeutics to Present at Sidoti Virtual Investor Conference
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Sidoti Virtual Conference. TransCode’s Chief Exe
Read more →RNAZTransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adeno
Read more →RNAZTransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced acceptance for publication by Frontiers in Oncology of a case study using TransCod
Read more →RNAZTransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Chardan 6th Annual Genetic Medicines Conference
Read more →RNAZTransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board. “Dr. Slack is one
Read more →RNAZTransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter ended June 30, 2022, and recent business p
Read more →RNAZTransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced a strategic alliance to advance Trans
Read more →RNAZTransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its intellectual property portfolio through the filing of a provisional patent applic
Read more →RNAZTransCode Therapeutics to Participate at BIO International Convention
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 in San Diego, CA. The in-person venue for the event is the San Diego Convention
Read more →RNAZTransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors First SBIR program milestone achieved in Q1 2022 BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeu
Read more →RNAZTransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the Fontainebleau Hotel in Miami Beach at 4441 Collins
Read more →RNAZTransCode Therapeutics Acquires Option for Radiotheranostic Technology
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, w
Read more →RNAZTransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for the first quarter ended March 31, 2022, and recent business progress. TransCo
Read more →RNAZTransCode Therapeutics’ CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce that its Co-Founder and Chief Technology Officer, Dr. Zdravka Medarova, will moderate the
Read more →RNAZTransCode Therapeutics Reports 2021 Results; Provides Business Update
BOSTON, March 31, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for 2021 and recent business progress. “2021 was a foundational year for TransC
Read more →RNAZTransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report
BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an interview with Co-Founder, President and CEO, Michael Dudley, will air on The RedChip
Read more →RNAZTransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders
BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern Univ
Read more →RNAZTransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific disco
Read more →RNAZTransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based
Read more →RNAZTransCode Therapeutics To Participate at MedInvest Oncology Investor Conference
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based
Read more →RNAZTransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results eIND application submission for TTX-MC138 anticipated in H1 2022 Boston, MA
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results eIND application submission for TTX-MC138 anticipated Boston, MA, Nov 15, 2021 - TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer ca
Read more →RNAZTransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer Boston, MA
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer Boston, MA, Sept. 30, 2021 - TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent
Read more →RNAZTransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results Completed initial public offering of common stock, raising $28.8 million in gross proceeds Awarded $2.3 million in funding from N
TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results Completed initial public offering of common stock, raising $28.8 million in gross proceeds Awarded $2.3 million in funding from NIH to support clinical evaluation of TTX-MC138 On trac
Read more →Competitive Position
How RNAZ ranks across every disease it competes inCompetitive Position is a premium feature
See how RNAZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial